| 1 | preventing | 8,452 |
| 2 | reversing | 400 |
| 3 | eradicating | 230 |
| 4 | combating | 150 |
| 5 | transmitting | 126 |
| 6 | averting | 34 |
| 7 | curbing | 27 |
| 8 | zymosan-induced | 9 |
| 9 | thiazolidinedione-induced | 6 |
| 10 | plato-defined | 5 |
| 11 | 24-h. | 4 |
| 12 | hot-air-dried | 4 |
| 13 | non-endovenous | 4 |
| 14 | peer-reported | 4 |
| 15 | alcohol-mediated | 3 |
| 16 | cd105+ | 3 |
| 17 | curcumin-supplemented | 3 |
| 18 | mhv-3-induced | 3 |
| 19 | non-thrombotic | 3 |
| 20 | noncluster | 3 |
| 21 | occlusoproximal | 3 |
| 22 | poly-pharmacy | 3 |
| 23 | ritonavir-resistant | 3 |
| 24 | 10,909 | 2 |
| 25 | 18,314 | 2 |
| 26 | 2009.idiopathic | 2 |
| 27 | 4707 | 2 |
| 28 | ammonia-induced | 2 |
| 29 | chhatrapati | 2 |
| 30 | conventional/non-conventional | 2 |
| 31 | kafr | 2 |
| 32 | mercury-induced | 2 |
| 33 | n-nitrosodiethylamine-mediated | 2 |
| 34 | non-venous | 2 |
| 35 | nonprocedure-related | 2 |
| 36 | pc-induced | 2 |
| 37 | photo-aged | 2 |
| 38 | placental-based | 2 |
| 39 | product-treated | 2 |
| 40 | qatif | 2 |
| 41 | randers | 2 |
| 42 | reformulating | 2 |
| 43 | salt-fed | 2 |
| 44 | sub-citrate | 2 |
| 45 | ≥3rd | 2 |
| 46 | 'yang- | 1 |
| 47 | 1-hour/24-hour | 1 |
| 48 | 131h | 1 |
| 49 | 13c6-glucose | 1 |
| 50 | 2,3-di-o-acetylation | 1 |
| 51 | 2,951 | 1 |
| 52 | 21,893 | 1 |
| 53 | 218/4951 | 1 |
| 54 | 250.000-350.000 | 1 |
| 55 | 3-iodochromones | 1 |
| 56 | 41° | 1 |
| 57 | 4633 | 1 |
| 58 | 5-16-year-old | 1 |
| 59 | adh-independent | 1 |
| 60 | adoptation | 1 |
| 61 | adp-ribosylcyclase | 1 |
| 62 | akt1- | 1 |
| 63 | alpha2,3- | 1 |
| 64 | anteior | 1 |
| 65 | anti-allodynics | 1 |
| 66 | axitinib-induced | 1 |
| 67 | bcg0878c-overexpressed | 1 |
| 68 | bilirrubins | 1 |
| 69 | blm- | 1 |
| 70 | bowel-based | 1 |
| 71 | bp-induced | 1 |
| 72 | bradypacing | 1 |
| 73 | cam-resistant | 1 |
| 74 | cdc/nhsn-defined | 1 |
| 75 | cgk | 1 |
| 76 | cip- | 1 |
| 77 | claudin-16/paracellin-1 | 1 |
| 78 | claw- | 1 |
| 79 | clock-hour-based | 1 |
| 80 | confidence- | 1 |
| 81 | coöperation | 1 |
| 82 | criminalizing | 1 |
| 83 | cross-tabulating | 1 |
| 84 | cryomedicine | 1 |
| 85 | ctf18 | 1 |
| 86 | curdlan-treated | 1 |
| 87 | da-level | 1 |
| 88 | dcm-patients | 1 |
| 89 | ddd-associated | 1 |
| 90 | deaths/disabilities | 1 |
| 91 | dha‑ | 1 |
| 92 | dismetabolic | 1 |
| 93 | dual-career | 1 |
| 94 | egcg-ameliorating | 1 |
| 95 | eight-days | 1 |
| 96 | epinephrine-stressed | 1 |
| 97 | esa-responsiveness | 1 |
| 98 | exercise-driven | 1 |
| 99 | first-psychotic | 1 |
| 100 | first-relapse | 1 |
| 101 | glabella-salivation | 1 |
| 102 | hapu | 1 |
| 103 | her-2-associated | 1 |
| 104 | hf+hno3+hcl | 1 |
| 105 | hf-weighted | 1 |
| 106 | high-density-cholesterol | 1 |
| 107 | hla-dq2- | 1 |
| 108 | identfying | 1 |
| 109 | imatinibresistant | 1 |
| 110 | integreview | 1 |
| 111 | inter-premolar | 1 |
| 112 | intercropping | 1 |
| 113 | interdicting | 1 |
| 114 | iron-normal | 1 |
| 115 | ivm-resistant | 1 |
| 116 | juxtaarticular | 1 |
| 117 | kick-starting | 1 |
| 118 | kles | 1 |
| 119 | language-learning-impaired | 1 |
| 120 | ln-nt-probnp | 1 |
| 121 | logbmi | 1 |
| 122 | low-gc | 1 |
| 123 | low-medium- | 1 |
| 124 | lsf-induced | 1 |
| 125 | lymph-nodal | 1 |
| 126 | lymphatic- | 1 |
| 127 | ma-hmos | 1 |
| 128 | macrophage-transplanted | 1 |
| 129 | male-predominant | 1 |
| 130 | melatonin-only | 1 |
| 131 | microvoids | 1 |
| 132 | mildly- | 1 |
| 133 | mmt- | 1 |
| 134 | multicenteric | 1 |
| 135 | murrel | 1 |
| 136 | n-pentane-cis-decaline | 1 |
| 137 | neath | 1 |
| 138 | non-efficacy | 1 |
| 139 | non-wilty | 1 |
| 140 | nonreporting | 1 |
| 141 | oe-exposed | 1 |
| 142 | off-sale | 1 |
| 143 | osteclastic | 1 |
| 144 | p0cy1 | 1 |
| 145 | p53dom/neg | 1 |
| 146 | pa-negative | 1 |
| 147 | papaverine- | 1 |
| 148 | peg-ifn/rbv-naïve | 1 |
| 149 | peptase | 1 |
| 150 | perioperative/liver/critically | 1 |
| 151 | pgn- | 1 |
| 152 | plantar- | 1 |
| 153 | plantar-type | 1 |
| 154 | polymyxin-resistant | 1 |
| 155 | pre-eimeria | 1 |
| 156 | pre-existed | 1 |
| 157 | pre-imatinib | 1 |
| 158 | preventional | 1 |
| 159 | professional-technical-managerial | 1 |
| 160 | prophase-l | 1 |
| 161 | pros-specific | 1 |
| 162 | pvc-associated | 1 |
| 163 | rajaei | 1 |
| 164 | repacking | 1 |
| 165 | rice/fruit | 1 |
| 166 | rsva | 1 |
| 167 | sars-coronavirus | 1 |
| 168 | scd1-modified | 1 |
| 169 | shgal-3-hela | 1 |
| 170 | shoe/cleat-type | 1 |
| 171 | submucoperichondrial | 1 |
| 172 | symptom-resolution | 1 |
| 173 | systemic-to-systemic | 1 |
| 174 | tamsulosin- | 1 |
| 175 | term/late | 1 |
| 176 | therapist-effect | 1 |
| 177 | trail-treated | 1 |
| 178 | tumorigenesis/tumor | 1 |
| 179 | ugt1a6*1 | 1 |
| 180 | unknown/no | 1 |
| 181 | unpassable | 1 |
| 182 | ureaplasma-negative | 1 |
| 183 | vc-induced | 1 |
| 184 | ventnor | 1 |
| 185 | verdun | 1 |
| 186 | vindictive | 1 |
| 187 | vitro-generated | 1 |
| 188 | vitro-synthesized | 1 |
| 189 | vivo/singleton | 1 |
| 190 | weakness- | 1 |
| 191 | wsc1δ | 1 |
| 192 | δlapb | 1 |
| 193 | €174/severe | 1 |
| 1 | 'yang- | 1 |
| 2 | 1-hour/24-hour | 1 |
| 3 | 10,909 | 2 |
| 4 | 131h | 1 |
| 5 | 13c6-glucose | 1 |
| 6 | 18,314 | 2 |
| 7 | 2,3-di-o-acetylation | 1 |
| 8 | 2,951 | 1 |
| 9 | 2009.idiopathic | 2 |
| 10 | 21,893 | 1 |
| 11 | 218/4951 | 1 |
| 12 | 24-h. | 4 |
| 13 | 250.000-350.000 | 1 |
| 14 | 3-iodochromones | 1 |
| 15 | 41° | 1 |
| 16 | 4633 | 1 |
| 17 | 4707 | 2 |
| 18 | 5-16-year-old | 1 |
| 19 | adh-independent | 1 |
| 20 | adoptation | 1 |
| 21 | adp-ribosylcyclase | 1 |
| 22 | akt1- | 1 |
| 23 | alcohol-mediated | 3 |
| 24 | alpha2,3- | 1 |
| 25 | ammonia-induced | 2 |
| 26 | anteior | 1 |
| 27 | anti-allodynics | 1 |
| 28 | averting | 34 |
| 29 | axitinib-induced | 1 |
| 30 | bcg0878c-overexpressed | 1 |
| 31 | bilirrubins | 1 |
| 32 | blm- | 1 |
| 33 | bowel-based | 1 |
| 34 | bp-induced | 1 |
| 35 | bradypacing | 1 |
| 36 | cam-resistant | 1 |
| 37 | cd105+ | 3 |
| 38 | cdc/nhsn-defined | 1 |
| 39 | cgk | 1 |
| 40 | chhatrapati | 2 |
| 41 | cip- | 1 |
| 42 | claudin-16/paracellin-1 | 1 |
| 43 | claw- | 1 |
| 44 | clock-hour-based | 1 |
| 45 | combating | 150 |
| 46 | confidence- | 1 |
| 47 | conventional/non-conventional | 2 |
| 48 | coöperation | 1 |
| 49 | criminalizing | 1 |
| 50 | cross-tabulating | 1 |
| 51 | cryomedicine | 1 |
| 52 | ctf18 | 1 |
| 53 | curbing | 27 |
| 54 | curcumin-supplemented | 3 |
| 55 | curdlan-treated | 1 |
| 56 | da-level | 1 |
| 57 | dcm-patients | 1 |
| 58 | ddd-associated | 1 |
| 59 | deaths/disabilities | 1 |
| 60 | dha‑ | 1 |
| 61 | dismetabolic | 1 |
| 62 | dual-career | 1 |
| 63 | egcg-ameliorating | 1 |
| 64 | eight-days | 1 |
| 65 | epinephrine-stressed | 1 |
| 66 | eradicating | 230 |
| 67 | esa-responsiveness | 1 |
| 68 | exercise-driven | 1 |
| 69 | first-psychotic | 1 |
| 70 | first-relapse | 1 |
| 71 | glabella-salivation | 1 |
| 72 | hapu | 1 |
| 73 | her-2-associated | 1 |
| 74 | hf+hno3+hcl | 1 |
| 75 | hf-weighted | 1 |
| 76 | high-density-cholesterol | 1 |
| 77 | hla-dq2- | 1 |
| 78 | hot-air-dried | 4 |
| 79 | identfying | 1 |
| 80 | imatinibresistant | 1 |
| 81 | integreview | 1 |
| 82 | inter-premolar | 1 |
| 83 | intercropping | 1 |
| 84 | interdicting | 1 |
| 85 | iron-normal | 1 |
| 86 | ivm-resistant | 1 |
| 87 | juxtaarticular | 1 |
| 88 | kafr | 2 |
| 89 | kick-starting | 1 |
| 90 | kles | 1 |
| 91 | language-learning-impaired | 1 |
| 92 | ln-nt-probnp | 1 |
| 93 | logbmi | 1 |
| 94 | low-gc | 1 |
| 95 | low-medium- | 1 |
| 96 | lsf-induced | 1 |
| 97 | lymph-nodal | 1 |
| 98 | lymphatic- | 1 |
| 99 | ma-hmos | 1 |
| 100 | macrophage-transplanted | 1 |
| 101 | male-predominant | 1 |
| 102 | melatonin-only | 1 |
| 103 | mercury-induced | 2 |
| 104 | mhv-3-induced | 3 |
| 105 | microvoids | 1 |
| 106 | mildly- | 1 |
| 107 | mmt- | 1 |
| 108 | multicenteric | 1 |
| 109 | murrel | 1 |
| 110 | n-nitrosodiethylamine-mediated | 2 |
| 111 | n-pentane-cis-decaline | 1 |
| 112 | neath | 1 |
| 113 | non-efficacy | 1 |
| 114 | non-endovenous | 4 |
| 115 | non-thrombotic | 3 |
| 116 | non-venous | 2 |
| 117 | non-wilty | 1 |
| 118 | noncluster | 3 |
| 119 | nonprocedure-related | 2 |
| 120 | nonreporting | 1 |
| 121 | occlusoproximal | 3 |
| 122 | oe-exposed | 1 |
| 123 | off-sale | 1 |
| 124 | osteclastic | 1 |
| 125 | p0cy1 | 1 |
| 126 | p53dom/neg | 1 |
| 127 | pa-negative | 1 |
| 128 | papaverine- | 1 |
| 129 | pc-induced | 2 |
| 130 | peer-reported | 4 |
| 131 | peg-ifn/rbv-naïve | 1 |
| 132 | peptase | 1 |
| 133 | perioperative/liver/critically | 1 |
| 134 | pgn- | 1 |
| 135 | photo-aged | 2 |
| 136 | placental-based | 2 |
| 137 | plantar- | 1 |
| 138 | plantar-type | 1 |
| 139 | plato-defined | 5 |
| 140 | poly-pharmacy | 3 |
| 141 | polymyxin-resistant | 1 |
| 142 | pre-eimeria | 1 |
| 143 | pre-existed | 1 |
| 144 | pre-imatinib | 1 |
| 145 | preventing | 8,452 |
| 146 | preventional | 1 |
| 147 | product-treated | 2 |
| 148 | professional-technical-managerial | 1 |
| 149 | prophase-l | 1 |
| 150 | pros-specific | 1 |
| 151 | pvc-associated | 1 |
| 152 | qatif | 2 |
| 153 | rajaei | 1 |
| 154 | randers | 2 |
| 155 | reformulating | 2 |
| 156 | repacking | 1 |
| 157 | reversing | 400 |
| 158 | rice/fruit | 1 |
| 159 | ritonavir-resistant | 3 |
| 160 | rsva | 1 |
| 161 | salt-fed | 2 |
| 162 | sars-coronavirus | 1 |
| 163 | scd1-modified | 1 |
| 164 | shgal-3-hela | 1 |
| 165 | shoe/cleat-type | 1 |
| 166 | sub-citrate | 2 |
| 167 | submucoperichondrial | 1 |
| 168 | symptom-resolution | 1 |
| 169 | systemic-to-systemic | 1 |
| 170 | tamsulosin- | 1 |
| 171 | term/late | 1 |
| 172 | therapist-effect | 1 |
| 173 | thiazolidinedione-induced | 6 |
| 174 | trail-treated | 1 |
| 175 | transmitting | 126 |
| 176 | tumorigenesis/tumor | 1 |
| 177 | ugt1a6*1 | 1 |
| 178 | unknown/no | 1 |
| 179 | unpassable | 1 |
| 180 | ureaplasma-negative | 1 |
| 181 | vc-induced | 1 |
| 182 | ventnor | 1 |
| 183 | verdun | 1 |
| 184 | vindictive | 1 |
| 185 | vitro-generated | 1 |
| 186 | vitro-synthesized | 1 |
| 187 | vivo/singleton | 1 |
| 188 | weakness- | 1 |
| 189 | wsc1δ | 1 |
| 190 | zymosan-induced | 9 |
| 191 | δlapb | 1 |
| 192 | €174/severe | 1 |
| 193 | ≥3rd | 2 |
| 1 | cd105+ | 3 |
| 2 | akt1- | 1 |
| 3 | hla-dq2- | 1 |
| 4 | alpha2,3- | 1 |
| 5 | lymphatic- | 1 |
| 6 | confidence- | 1 |
| 7 | papaverine- | 1 |
| 8 | 'yang- | 1 |
| 9 | blm- | 1 |
| 10 | low-medium- | 1 |
| 11 | pgn- | 1 |
| 12 | tamsulosin- | 1 |
| 13 | cip- | 1 |
| 14 | plantar- | 1 |
| 15 | weakness- | 1 |
| 16 | mmt- | 1 |
| 17 | claw- | 1 |
| 18 | mildly- | 1 |
| 19 | 24-h. | 4 |
| 20 | 250.000-350.000 | 1 |
| 21 | ugt1a6*1 | 1 |
| 22 | claudin-16/paracellin-1 | 1 |
| 23 | 2,951 | 1 |
| 24 | 218/4951 | 1 |
| 25 | p0cy1 | 1 |
| 26 | 4633 | 1 |
| 27 | 21,893 | 1 |
| 28 | 18,314 | 2 |
| 29 | 4707 | 2 |
| 30 | ctf18 | 1 |
| 31 | 10,909 | 2 |
| 32 | pre-eimeria | 1 |
| 33 | shgal-3-hela | 1 |
| 34 | rsva | 1 |
| 35 | pre-imatinib | 1 |
| 36 | δlapb | 1 |
| 37 | low-gc | 1 |
| 38 | pros-specific | 1 |
| 39 | 2009.idiopathic | 2 |
| 40 | dismetabolic | 1 |
| 41 | systemic-to-systemic | 1 |
| 42 | multicenteric | 1 |
| 43 | non-thrombotic | 3 |
| 44 | first-psychotic | 1 |
| 45 | osteclastic | 1 |
| 46 | mhv-3-induced | 3 |
| 47 | ammonia-induced | 2 |
| 48 | axitinib-induced | 1 |
| 49 | pc-induced | 2 |
| 50 | vc-induced | 1 |
| 51 | thiazolidinedione-induced | 6 |
| 52 | lsf-induced | 1 |
| 53 | zymosan-induced | 9 |
| 54 | bp-induced | 1 |
| 55 | mercury-induced | 2 |
| 56 | salt-fed | 2 |
| 57 | photo-aged | 2 |
| 58 | scd1-modified | 1 |
| 59 | hot-air-dried | 4 |
| 60 | cdc/nhsn-defined | 1 |
| 61 | plato-defined | 5 |
| 62 | language-learning-impaired | 1 |
| 63 | placental-based | 2 |
| 64 | bowel-based | 1 |
| 65 | clock-hour-based | 1 |
| 66 | oe-exposed | 1 |
| 67 | bcg0878c-overexpressed | 1 |
| 68 | epinephrine-stressed | 1 |
| 69 | trail-treated | 1 |
| 70 | curdlan-treated | 1 |
| 71 | product-treated | 2 |
| 72 | her-2-associated | 1 |
| 73 | pvc-associated | 1 |
| 74 | ddd-associated | 1 |
| 75 | n-nitrosodiethylamine-mediated | 2 |
| 76 | alcohol-mediated | 3 |
| 77 | nonprocedure-related | 2 |
| 78 | vitro-generated | 1 |
| 79 | hf-weighted | 1 |
| 80 | macrophage-transplanted | 1 |
| 81 | curcumin-supplemented | 3 |
| 82 | peer-reported | 4 |
| 83 | pre-existed | 1 |
| 84 | vitro-synthesized | 1 |
| 85 | 5-16-year-old | 1 |
| 86 | ≥3rd | 2 |
| 87 | off-sale | 1 |
| 88 | unpassable | 1 |
| 89 | cryomedicine | 1 |
| 90 | n-pentane-cis-decaline | 1 |
| 91 | plantar-type | 1 |
| 92 | shoe/cleat-type | 1 |
| 93 | €174/severe | 1 |
| 94 | adp-ribosylcyclase | 1 |
| 95 | peptase | 1 |
| 96 | 13c6-glucose | 1 |
| 97 | first-relapse | 1 |
| 98 | term/late | 1 |
| 99 | sub-citrate | 2 |
| 100 | ureaplasma-negative | 1 |
| 101 | pa-negative | 1 |
| 102 | vindictive | 1 |
| 103 | peg-ifn/rbv-naïve | 1 |
| 104 | qatif | 2 |
| 105 | p53dom/neg | 1 |
| 106 | curbing | 27 |
| 107 | bradypacing | 1 |
| 108 | repacking | 1 |
| 109 | intercropping | 1 |
| 110 | reversing | 400 |
| 111 | combating | 150 |
| 112 | eradicating | 230 |
| 113 | cross-tabulating | 1 |
| 114 | reformulating | 2 |
| 115 | egcg-ameliorating | 1 |
| 116 | interdicting | 1 |
| 117 | preventing | 8,452 |
| 118 | kick-starting | 1 |
| 119 | averting | 34 |
| 120 | nonreporting | 1 |
| 121 | transmitting | 126 |
| 122 | identfying | 1 |
| 123 | criminalizing | 1 |
| 124 | 131h | 1 |
| 125 | neath | 1 |
| 126 | rajaei | 1 |
| 127 | logbmi | 1 |
| 128 | chhatrapati | 2 |
| 129 | cgk | 1 |
| 130 | prophase-l | 1 |
| 131 | lymph-nodal | 1 |
| 132 | submucoperichondrial | 1 |
| 133 | professional-technical-managerial | 1 |
| 134 | occlusoproximal | 3 |
| 135 | iron-normal | 1 |
| 136 | preventional | 1 |
| 137 | conventional/non-conventional | 2 |
| 138 | hf+hno3+hcl | 1 |
| 139 | murrel | 1 |
| 140 | da-level | 1 |
| 141 | high-density-cholesterol | 1 |
| 142 | exercise-driven | 1 |
| 143 | 2,3-di-o-acetylation | 1 |
| 144 | coöperation | 1 |
| 145 | adoptation | 1 |
| 146 | glabella-salivation | 1 |
| 147 | symptom-resolution | 1 |
| 148 | vivo/singleton | 1 |
| 149 | verdun | 1 |
| 150 | unknown/no | 1 |
| 151 | ln-nt-probnp | 1 |
| 152 | inter-premolar | 1 |
| 153 | juxtaarticular | 1 |
| 154 | dual-career | 1 |
| 155 | noncluster | 3 |
| 156 | kafr | 2 |
| 157 | anteior | 1 |
| 158 | tumorigenesis/tumor | 1 |
| 159 | ventnor | 1 |
| 160 | 1-hour/24-hour | 1 |
| 161 | anti-allodynics | 1 |
| 162 | microvoids | 1 |
| 163 | deaths/disabilities | 1 |
| 164 | kles | 1 |
| 165 | 3-iodochromones | 1 |
| 166 | bilirrubins | 1 |
| 167 | ma-hmos | 1 |
| 168 | randers | 2 |
| 169 | esa-responsiveness | 1 |
| 170 | dcm-patients | 1 |
| 171 | non-venous | 2 |
| 172 | non-endovenous | 4 |
| 173 | sars-coronavirus | 1 |
| 174 | eight-days | 1 |
| 175 | therapist-effect | 1 |
| 176 | rice/fruit | 1 |
| 177 | male-predominant | 1 |
| 178 | cam-resistant | 1 |
| 179 | ivm-resistant | 1 |
| 180 | polymyxin-resistant | 1 |
| 181 | ritonavir-resistant | 3 |
| 182 | imatinibresistant | 1 |
| 183 | adh-independent | 1 |
| 184 | hapu | 1 |
| 185 | integreview | 1 |
| 186 | non-efficacy | 1 |
| 187 | poly-pharmacy | 3 |
| 188 | perioperative/liver/critically | 1 |
| 189 | melatonin-only | 1 |
| 190 | non-wilty | 1 |
| 191 | dha‑ | 1 |
| 192 | 41° | 1 |
| 193 | wsc1δ | 1 |